Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was...
INVITATION FOR EXPRESSION OF INTEREST - For Divestiture of 'Canwill Holdings (Pvt) Ltd'
COLOMBO, Sri Lanka, Jan. 20, 2026 /PRNewswire/ -- The Government of Sri Lanka (GoSL) intends to divest the 100% shareholding in Canwill, the parent company to Sinolanka Hotels & Spa (Pvt) Ltd (Sinolanka) and Helanco Hotels & Spa (Pvt) Ltd...
Ericsson announces proposed headcount reduction in Sweden
STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Ericsson (NASDAQ: ERIC) today announces proposed staff reductions in Sweden as part of measures aimed at ensuring the Company's competitive position. The proposed staff reduction is part of global initiatives...
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the...
Netflix Supports Warner Bros. Discovery Board's Commitment to Merger Agreement
Following Comprehensive and Rigorous Review, Warner Bros. Discovery Board Continues to Recommend Stockholders Approve Netflix Agreement More Information on How Netflix and Warner Bros. Will Define the Next Century of Storytelling Available at...
Autoliv Provides Update Regarding Resignation Date of Fredrik Westin
STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced that Fredrik Westin has agreed with the Company to amend his resignation date to be effective March...
Cloopen Announces Receipt of Preliminary Non-Binding "Going Private" Proposal
BEIJING, Dec. 24, 2025 /PRNewswire/ -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company") today announced that its Board of Directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal"), dated...
When East Meets West: Global Youth Sculpture Cyber Program Fosters Cultural Dialogue
NANJING, China, Dec. 23, 2025 /PRNewswire/ -- A report from Jiangsunow. "Sculpting Thoughts" Global Youth Sculpture Cyber Program Watch video: https://www.youtube.com/watch?v=T8zn10Ke1xs&t=5s A unique digital art initiative is bridging ancient...
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated...
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT...